Agoracom Blog Home

Posts Tagged ‘Marijuana’

« Older Entries
Newer Entries »

NORTHBUD $NBUD.ca – #Cannabis Canada: #Pot industry added nearly $8B to #GDP in August, #StatsCan says $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 4:31 PM on Tuesday, November 5th, 2019

SPONSOR: NORTHBUD (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

NBUD: CSE
—————————–

Cannabis Canada: Pot industry added nearly $8B to GDP in August, StatsCan says

Cannabis sales in Canada expected to double next year to $3.16B: analyst 

Canaccord Genuity cannabis analyst Matt Bottomley expects revenue in Canada’s legal pot sector to more than double next year despite slower-than-expected growth. Bottomley said in a research note to clients that Canada’s cannabis industry should expect $3.16 billion in revenue in 2020, up from the $1.46 billion forecast for 2019. He added Canada’s cannabis retail figures should see a five per cent reduction in overall sales in September from the prior month to $121 million, but said subsequent growth should advance at a five-per-cent monthly clip. Bottomley expects growth in the recreational market to increase by just 7.5 per cent in 2020. Alongside its latest estimates for the Canadian cannabis industry, Canaccord’s analysts have revised sales projections for some of the country’s largest licensed producers such as Canopy Growth, Aphria and Aurora Cannabis.

BRNT secures multiyear white label deal with Valens GroWorks for 2.2M vape pens

BRNT Group, a company which has made its name making high-end cannabis accessories, is getting into the vape game. The company announced on Thursday a partnership with Valens GroWorks to produce a minimum of 2.2 million vape pens over the next two years. The deal, which is believed to be one of the largest publicly announced multi-year white label agreements, is expected to generate over $50-million in gross revenue for Valens, according to a statement released by both companies. The vape devices are expected to be available in select markets starting in the first quarter of next year and roll out across Canada later in the year.

Canadian pot producer hires helicopter to avoid possible frost on outdoor grow

Looking for a novel way to ensure your outdoor crop won’t be impacted by frost? Give your local helicopter pilot a call. That’s what 48North did, according to an Instagram post published by Devin Piche, the company’s master grower. A helicopter is able to float above an agricultural crop and essentially suck up cold air upward away from plants which could be damaged by a potential frost. “The helicopter was used to move warm air in a temperature inversion down into the crop area to keep the temperature above freezing,” according to Connor Whitworth, a 48North spokesperson. The cannabis producer is harvesting the remaining cannabis plants it is growing in its Good:Farm facility. Whitworth declined to further comment on 48North’s outdoor harvest, which it has previously stated expects to yield 40,000 kilograms of cannabis.

Alberta eyes 500 pot shops by 2021, no consumption lounges planned: regulatory official

Alberta is already the country’s market leader in the pot retail space – and it looks like it could get even larger.  Alberta Gaming, Liquor and Cannabis expects its store count to grow to over 500 within two years, according to the Calgary Herald, citing an official with the provincial regulator. The regulator has already green lit 306 retail outlets across the province, a number that will likely grow by 200 by 2021. However, cannabis consumption lounges don’t appear yet to be coming out anytime soon and would require legislative approval to establish those types of facilities, the official said.

Canada’s cannabis industry contributed nearly $8B to GDP in August: StatsCan

Canada’s cannabis sector – both the legal and illegal market – contributed $7.92 billion to the country’s gross domestic product in August, a figure that continues to grow from the $7.02 billion last October when recreational cannabis was legalized and above the revised $7.79 billion mark made in July, according to new data published by Statistics Canada on Thursday. The StatsCan figures also show Canada’s legal cannabis industry has grown by 116 per cent in the first 11 months since recreational marijuana was legalized. The black market’s cannabis output has fallen by 22 per cent in that same time, according to StatsCan estimates.

Source: https://www.bnnbloomberg.ca/cannabis-canada-pot-industry-added-nearly-8b-to-gdp-in-august-statscan-says-1.1341044

Tags: , , , , , , , ,
Posted in All Recent Posts, North Bud Farms Inc | Comments Off on NORTHBUD $NBUD.ca – #Cannabis Canada: #Pot industry added nearly $8B to #GDP in August, #StatsCan says $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Empower Clinics $CBDT.ca Is Laser Focused On The U.S. #CBD Opportunity $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 11:41 AM on Tuesday, November 5th, 2019

Empower Clinics Is Laser Focused On The U.S. CBD Opportunity

  • A leading owner/operator of physician staffed health and pain management clinics.
  • Patient database of over 165,000 patients 
  • Platform generating $4MM USD in revenue annually (2019)
  • Proprietary technology platforms including Electronic Health Records portal and e-Commerce for CBD product distribution
  • Launching CBD extraction facility
  • First extraction system capacity = 6,000 Kg per year.
  • CBD based products are poised to be a $20B global industry by 2022
  • Medical cannabis is poised to be a $100B global industry by 2025

By Anthony Varrell

The last few months have been difficult for the cannabis sector and the recent decline has caught the attention of new capital. Over the last few months, we attended several conferences and met with new venture and private equity funds that are taking a hard look at the cannabis sector following the recent pullback.

Following our meeting with these funds, we became increasingly excited about how the sector will perform during 2020. During the final quarter of the year, we expect to see more tax loss selling and this is a trend to be monitoring. On average, we have seen a drastic improvement from a fundamental standpoint when analyzing companies that are focused on the cannabis sector. This is a trend that we expect to continue on a going forward basis and believe the recent weakness has created opportunity.

The US represents one of the most exciting cannabis markets and we have noticed a significant increase in the amount of interest in this burgeoning market. Over the next year, we expect to see further interest in the US market and expect deregulation to be a catalyst for the businesses that are levered to this opportunity.

During the last month, we have been highly focused on the US cannabis market and have been working to identify companies with specific criteria. When analyzing these cannabis businesses, we are looking for companies that are: 1) led by a management team that is focused on execution and creating value for shareholders; 2) have visible growth prospects and substantial potential catalysts for growth; 3) are attractively valued or misunderstood by the market; and 4) that are levered to states with burgeoning cannabis markets.

One company that we believe that meets this criteria is Empower Clinics (CBDT.CN) (EPWCF) and today, we have issued on the US cannabis business. The company has substantial growth prospects, a diverse business model, and represents a multi-faceted growth opportunity. Over the next year, Empower is expected to report strong revenue growth as the management team continues to execute on its expansion and advance the franchise model aspect of the business.

Growing Through Strategic Partnerships

One of the reasons we are excited about Empower is due the focus on securing strategic partners to support growth. From a resource’s standpoint, the company has been able to expand into markets that are both efficient and effective. Going forward, we expect to see Empower benefit from the relationships that it has formed and believe that the market underappreciates this aspect of the story.

A few weeks ago, Empower announced a major milestone and entered into a letter of intent to form a joint venture with Heritage Cannabis Holdings (CANN.CN) for the extraction of hemp for CBD oil production, and formulated CBD products. The joint venture will be owned 50/50 by each company and we are bullish on the growth prospects associated with this initiative.

Heritage, via its wholly owned subsidiary Purefarma Solutions, will install extraction units and related downstream extraction equipment inside Empower’s existing 5,000 sq. ft. licensed hemp processing facility. Purefarma will also train and supervise the staff on the proprietary methods of extraction and oil production that it produces in Canada.

We are favorable on the expertise that each company brings to the joint venture and expect this to play a key role in the success of the operation. Going forward, the joint venture plans to secure high quality hemp supply from local growers as construction is completed on the facility. Once operational, the joint venture will start producing proprietary branded products for Empower’s corporately owned physician staffed health clinics in Washington State, Oregon, Nevada, and Arizona.

Highly Focused on the US CBD Market

Another attractive aspect of the Empower story is related to the hemp-derived CBD extraction facility in Oregon. The company is in the process of constructing a facility equipped with a state-of-the-art extraction system (expected to produce approx. 6,000 kg of extracted product per year) and this should prove to be a major revenue driver in 2020.

Empower has commenced the process to access the more than 1,300 licensed hemp farmers in Oregon and we are favorable on this. These cultivators are known to produce some of the highest quality hemp bio-mass in the US and we find this be significant. Quality of products has become very important following the issues over at Juul and we believe that the joint venture has done a great job by focusing of safety and consistency.

From a distribution standpoint, the footprint that Empower has throughout the US will play a key role in the success of the CBD business. Through Sun Valley Health, a subsidiary of Empower, the company has access to more than 165,000 patients. Through company owned and franchised cannabis clinics, Empower will be able to market to large potential customer base that is clearly open to cannabis.

Empower recently launched an e-commerce platform to sell company branded hemp-derived CBD based products as well as premium health and wellness supplements. Over the next year, we expect to see the company’s CBD product line gain traction within its clinic network and will monitor this aspect of the story.

An Opportunity that is Flying Under the Radar

Over the next year, we expect to see Empower benefit from having a multi-faceted growth model and additional revenue streams. Going forward, we are most excited about the growth prospects associated with the CBD market and the clinic franchise opportunity. Empower has visible growth prospects and we expect 2020 to be a banner year for the business.

One of the most significant developments of 2019 for Empower was the change in the management team. We believe that the transition has been smooth and are favorable on the verticals that the new leadership team has the business focused on. We believe that the new management team better understands how to utilize its assets to capitalize on the cannabis industry and find this to be significant.

During the last year, Empower has transitioned from being only focused on cannabis clinics to being a multi-faceted growth story with leverage to the CBD market. We believe that the CBD opportunity represents low hanging fruit for the company and this is primarily due to the relationships it has with consumers through the clinics.

Source: https://technical420.com/cannabis-article/empower-clinics-is-laser-focused-on-the-u-s-cbd-opportunity/#

Tags: , , , , , ,
Posted in Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca Is Laser Focused On The U.S. #CBD Opportunity $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca

PRIMO Nutraceuticals Inc. $PRMO.ca – Ask Our Experts: What’s The Big Deal About #CBD? $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 5:54 PM on Monday, November 4th, 2019

SPONSOR:  PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) provides strategic capital to the thriving cannabis cultivation sector through ownership and development of commercial real estate properties. The company also offers fully built out turnkey facilities equipped with state-of-the-art growing infrastructure to cannabis growers and processors. Click here for more info.

Ask Our Experts: What’s The Big Deal About CBD?

  • CBD is used by all types of consumers, purchasing CBD-infused products for a variety of reasons
  • A recent Gallup survey found that one in seven Americans report using CBD for a range of medical and therapeutic purposes

By New Frontier Data

Q: There is a lot of media coverage about CBD, and it seems to be appearing all over the place. Who is buying all the CBD products?

A: CBD stands for cannabidiol, the second-most popular among active ingredients of the cannabis sativa plant. Cannabis contains hundreds of cannabinoids, each of which presents unique qualities and potential benefits.

CBD is used by all types of consumers, purchasing CBD-infused products for a variety of reasons. A recent Gallup survey found that one in seven Americans report using CBD for a range of medical and therapeutic purposes.

With passage of the 2018 U.S. Farm Bill which federally legalized hemp for the first time since World War II, the market for hemp-derived CBD products has seen explosive growth. Mass-marketed, hemp-derived CBD products have found their way onto retail shelves everywhere from grocery stores, coffee shops, and cosmetics retailers to veterinarians’ offices and nutritional supplement shops nationwide.

That said, there remains confusion regarding to what extent CBD is legal. The DEA has asserted that only GW Pharmaceutical’s patented Epidiolex is legally permitted to incorporate CBD oil in products. Yet attorney Garrett Graff of Hoban Law Group, who specializes in cannabis law and is part of a group who brought an appeal against the DEA ruling, has challenged that.

“It’s our understanding that cannabinoids derived from industrial hemp so long as below the 0.3 percent THC threshold are, in fact, lawful pursuant to the farm bill under federal law,” Graff posited. Since the FDA has not approved any CBD products at all, “at this point, we simply agree to disagree, and those products remain on the marketplace,” he explained.

New Frontier Data is engaged in several ongoing CBD research projects examining the marketplace in the United States and globally, and expects to release several reports about CBD consumer behaviors, patterns of use, and engagement with the market. Among the first slated for release as part of New Frontier Data’s upcoming Cannabis Consumer Insight Series of white papers is Marijuana Consumers’ CBD Use, examining the preferences and behaviors of consumers already familiar with cannabis and cannabis-derived products.

Findings from the research indicate that nearly a third (30%) of cannabis consumers are using CBD products, or nearly twice the previously reported rate among the general population. Such consumers also tend to be women (57%), especially under the age of 35 (43%), consistent with much of the current marketing of CBD products as health and wellness brand targeted specifically to women consumers.

Other key insights from the report found that:

Cannabis consumers who purchase CBD-only products are high-retention customers: Among cannabis consumers who purchased a CBD product, the overwhelming majority (85%) indicated that they were likely to make additional CBD purchases within the next six months. The current market is at an inflection point for CBD brands, as consumers are enthusiastically purchasing and trying these products, but most likely have weak brand loyalty. Identifying core consumers and developing a unique brand identity in the CBD space is am imperative for success in the near term.

Understanding the specific cannabis consumers who are most interested in CBD will be key to capturing the most lucrative consumer segment: New Frontier Data has identified nine fundamental “Cannabis Consumer Archetypes“. Among those categorized cannabis consumers, it is the Modern Lifestylers, Medical Purists, and Functional Dependents who are most likely to have purchased a CBD product. However, as access to CBD products increases, it is expected that a broader base of consumers will integrate CBD into both their daily lives and as a complement to current cannabis use.

Source: https://www.benzinga.com/markets/cannabis/19/11/14717727/ask-our-experts-whats-the-big-deal-about-cbd

Tags: , , , , , , ,
Posted in Bougainville Ventures, PRIMO Nutraceuticals Inc. | Comments Off on PRIMO Nutraceuticals Inc. $PRMO.ca – Ask Our Experts: What’s The Big Deal About #CBD? $CROP.ca $VP.ca NF.ca $MCOA

NORTHBUD $NBUD.ca – #Edible #CBD Products Offer Consumers a New Health Trend $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 4:00 PM on Thursday, October 31st, 2019

SPONSOR: NORTHBUD (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

NBUD: CSE
—————————–

Edible CBD Products Offer Consumers a New Health Trend

  • North American consumer spending on cannabis-infused foods and drinks reached USD 1.5 Billion in 2018, according to data compiled by Arcview Market Research and BDS Analytics,
  • By 2022, the two firms suggest that edible sales are on track to reach USD 4.1 Billion

NEW YORK, Oct. 31, 2019 – Consumer trends constantly require industries to adapt in order to thrive among the competition. Specifically, the food and beverage industry is one of the fastest evolving markets because of constant changes in consumer demands. Nowadays, the increasing demand for healthier and more organic options is prompting manufacturers to produce alternatives to sugar-packed drinks and fatty snacks. Instead, consumers are looking for products that are processed with healthier sustainable ingredients, proteins, vitamins, and antioxidants. Notably, many consumers have turned to the beverage industry for functional drinks such as kombucha. A functional drink is a type of beverage that typically conveys a health benefit such as being packed with performance-enhancing agents like nootropics and amino acids. Consequently, the growing demand in the functional beverage market sparked interest within the CBD market. CBD is a derivative of the hemp plant, which falls under the cannabis family.

Typically, cannabis is associated with its marijuana component, which causes psychoactive effects because of its heavy THC concentrate. However, hemp does not cause psychoactive effects because the main compound is CBD. THC and CBD are widely different in their biological makeup, but because they derive from the cannabis plant, regulators deemed both compounds to be unsafe for consumers. However, extensive research has uncovered that CBD provides therapeutic and health benefits, which then led to the rapid emergence of CBD-based products. As such, North American consumer spending on cannabis-infused foods and drinks reached USD 1.5 Billion in 2018, according to data compiled by Arcview Market Research and BDS Analytics, By 2022, the two firms suggest that edible sales are on track to reach USD 4.1 Billion.

Typically, most people consume CBD to simply relax. However, clinical trials have proven that CBD can also provide medical benefits. Specifically, patients suffering from chronic ailments such as severe pain, cancer, arthritis, and epilepsy can consume CBD drinks to subdue the symptoms. And while CBD is quickly permeating throughout global regions, the North American market is the primary driver because of legality stance. Canada moved to legalize cannabis entirely back in late 2018, which prompted a spur of recreational demand. On the other hand, the U.S. passed the Farm Bill in 2018, which legalized hemp-derived CBD products. Shortly after, stores across the nation began to commercialize CBD goods.

Now, consumers can easily purchase products such as tinctures, topicals, oils, and edibles at their local convenience stores or online e-commerce platforms. However, the CBD beverage market is one of the most popular segments because consumers can easily purchase a CBD-based tincture and add droplets of CBD into their beverage. Generally, CBD can be found within beverages such as soda, juice, coffee, wine, water, and even alcohol. However, consumers can also add CBD-based powders into their beverages and some producers have even mentioned that powders are much better in terms of solubility. Overall, the cannabis-infused beverage industry is quickly gaining traction, however, some beverage producers are still evaluating the industry.

Nonetheless, a handful of corporations such as the alcohol industry, have already dove into the marketplace and are already marking their presence.  “Everyone in the industry recognizes that CBD-infused beverages are going to be one of the largest category opportunities in all of CBD,” said Ben Witte, the Founder and Chief Executive Officer of Recess, a company producing CBD-infused sparkling water. “As a result of that, a lot of the suppliers in the supply chain have innovated to create a format that is soluble in beverages.”

Source: https://www.prnewswire.co.uk/news-releases/edible-cbd-products-offer-consumers-a-new-health-trend-884112693.html

Tags: , , , , , , , , ,
Posted in North Bud Farms Inc | Comments Off on NORTHBUD $NBUD.ca – #Edible #CBD Products Offer Consumers a New Health Trend $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

PRIMO Nutraceuticals Inc. $PROM.ca Harvests 13,000 lbs of Dried Bio-mass from Oregon Hemp Farm $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 8:24 AM on Wednesday, October 30th, 2019
  • Company has completed a harvest totaling 13,000 lbs of dried bio-mass of hemp from the Oregon hemp farm.
  • The dried bio-mass hemp is currently being stored at a local drying facility located near Eugene, Oregon.
  • The value for the crop in its current state is estimated to be worth $200,000 – $300,000 USD.

VANCOUVER, British Columbia, Oct. 30, 2019 — PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) (“Primo” or the “Company”)is pleased to announce that further to the Company news release dated October 1, 2019 the Company has completed a harvest totaling 13,000 lbs of dried bio-mass of hemp from the Oregon hemp farm. The dried bio-mass hemp is currently being stored at a local drying facility located near Eugene, Oregon. The value for the crop in its current state is estimated to be worth $200,000 – $300,000 USD. This will be added to the 28 kilo grams of crude oil currently in inventor from last year’s harvest. 

The completion of the 2019 harvest season is a major milestone for the company and for the hemp farm in Oregon, as this is the first year hemp has been federally legal since the Farm Bill was passed. This year in Oregon alone there are nearly 63,000 acres registered growing hemp compared to the 11,500 acres growing hemp registered in 2018. This is a significant increase in the amount of hemp being grown, which solidifies the Primo strategy of providing drying facilities to the ever growing hemp market in Oregon. Primo plans to have its first drying facility built and in operation by the end of the first quarter of next year.

President, Andy Jagpal Comments:

“I am very proud and excited with the amount of dried hemp that was harvested as it surpassed our expectations by a few thousand pounds. During a time in the cannabis market where companies have spent tens of millions of dollars building out facilities and cultivation infrastructure and have little to show for it, we have two harvests under our belt and product in inventory ready for sale. Together with this year’s harvest and last year’s inventory we estimate our inventory alone to be worth between $400,000 and $500,000 USD.”

VP Sales & Distribution, Andy Dhaliwal Comments:

“The on-hand inventory and quality of the hemp as starting material is a major advantage in the current marketplace. While the revenue opportunities from the harvest are extremely promising, the hemp processing infrastructure supports the expansion of our in-house product lines, and increases our white-label offering to the USA market as well. Both of which are tremendous assets for the company.”

About Primo Nutraceuticals, Inc.

Primo Nutraceuticals Inc. (“Primo” or the “Company”) provides strategic capital to the thriving cannabis cultivation sector through ownership and development of commercial real estate and farm friendly properties. Primo is dedicated to funding the rapid growth in production, processing, retail and branding of cannabis and cannabis related products in Canada and the United States. Primo provides fully built out turnkey facilities equipped with state-of-the-art growing infrastructure to cannabis growers and processors. In addition to the Company’s flagship hemp project in Oregon State and the Greenhouse campus in Washington State, Primo has invested in several brands and is pursuing partnerships with retailers and distribution companies in Canada and the United States. Primo’s management is in the process of building a corporate road map to further vertically integrate the Company, specifically by way of “Primo” branded retail outlets – offering “Thrive,” “Primo,” and a selection of curated partner brands. The Company possesses proprietary formulas for cannabis edibles, topical, and tinctures. Primo is focused on building a strong presence in the hemp industry with the objective of extracting and selling cannabinoids (CBD) products in both Canada and the United States.

On behalf of the Board of Directors
PRIMO NUTRACEUTICALS INC.

Andy Jagpal, President and Director

To learn more about what this news means to the shareholders visit https://marketnewsfirst.com/primo-nutraceuticals, as well as on the company’s site.

For further information, please contact Zoltan, IR Representative at: 604-722-0305 [email protected]. Or toll free at 1-877-517-7816.

http://primoceuticals.com/
https://twitter.com/prmonutra
www.thriveCBD.org

FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

No regulatory authority has approved or disapproved the information contained in this news release.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ddc63988-72ec-4630-a25d-5d418ba2ea1b

Tags: , , , , , ,
Posted in Bougainville Ventures, Featured, PRIMO Nutraceuticals Inc. | Comments Off on PRIMO Nutraceuticals Inc. $PROM.ca Harvests 13,000 lbs of Dried Bio-mass from Oregon Hemp Farm $CROP.ca $VP.ca NF.ca $MCOA

NORTHBUD $NBUD.ca – ‘It is quite amazing’: #CBD oil entering the mainstream $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 10:26 AM on Friday, October 18th, 2019

SPONSOR: NORTHBUD (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

NBUD: CSE
—————————–

‘It is quite amazing’: CBD oil entering the mainstream

By James Pugh

Some people are infusing the cannabis extract in cocktails, others are buying it in the form of dog treats, while many more are using it as a form of pain relief.

Unlike tetrahydrocannabinol, the psychoactive extract of the cannabis plant commonly known as THC, cannabidiol doesn’t cause users to get high.

And it is legal in the UK, assuming it does not contain one part in 10,000 of THC.

“When I first got involved with CBD I wanted to know what it was all about,” says Richard Butler, part of the management team at CBD Virtue, between Bridgnorth and Wolverhampton.

“It is still new in the UK.”

Some of the products

His company uses CBD to make products such as tablets, oils, body creams and balms.

Mr Butler says people are turning to CBD products to alleviate symptoms from physical ailments like pain and inflammation as well as mental ones like anxiety and depression.

At present, use of the oil is largely unregulated, and clinical trials into its usefulness are ongoing, but Mr Butler says he has witnessed its benefits.

“You learn more from the responses and feedback you get from customers,” he says. “It helps with pain relief, mental issues, anxieties.

“It also helps with eczema, psoriasis and acne – it is quite amazing actually.

“A lot of our initial customers were 40 plus and many were buying products for the younger generation.

Dean Burke using a CBD Pod Filler at CBD Virtue

“What has amazed me is the amount of depression and anxiety that exists among teenagers up to people in their late 20s.”

CBD oil, its proponents say, offers numerous benefits, from pain relief to reducing anxiety. As an anticonvulsant, it may also help treat neurological disorders such as epilepsy and multiple sclerosis.

CBD is also one of the biggest buzzwords in food and drink. It has been hailed the next big thing, with more and more chefs and producers using the products in their recipes.

After already taking other countries by storm, more businesses in the UK are looking to tap into the market.

Ross Burke viewing the product range at CBD Virtue

Mr Butler insists he has seen some significant success stories of people using the product for remedial purposes.

“I know someone who suffered with Parkinson’s for years who every time they woke up their whole body would be shaking and during the day they would shake out of control,” he says.

“I said ‘try this’ and within two weeks they went from their whole body shaking to feeling a slight twitch in their first finger and thumb.

“I am not allowed to say it cures cancer, but cancer sufferers are using it. There was someone who had skin cancer and it helped clear up blisters on their skin.

“My partner was on a lot of medication for various things and after taking four or five drops a day her stress and anxiety has gone.”

The product’s relationship to recreational cannabis also means that some people are reluctant to accept its use, and the medical benefits it provides have still to be proven beyond doubt.

But Mr Butler insists that the hemp-derived oil should be trusted.

“It is from a natural product that has been around for years,” he says. “Initially people were sceptical because it relates to cannabis. Yes, it is derived from cannabis plant, but the ‘high’ has been removed with the remedial side left behind.

The management team at CBD Virtue: Dean Burke, Richard Butler, Shannon Fyfe and Ross Burke

“We had the over 50s saying ‘ yeah but it’s cannabis, it’s cannabis’, but once you have explained to them they are willing to try it.

“A big part of my role has been educational. I would spend about two hours a day on Facebook educating people and answering a lot of questions.

“Initially it is getting people to try it, then after they see how effective it is they speak about it to their friends and family – a lot of it comes down to word of mouth.”

The plant is grown in Colorado in the USA, and a powdered form of the product is sent to the UK for the oil to be extracted by Richard’s team.

CBD Virtue employs 16 people, and is looking to double that by moving to larger premises to cope with demand.

Richard says: “We have a lab which is about 15ft by 20ft where a lot of our mixing is done. We also have another facility where we do the bottling up and everything else.

Jean Price packing up an order at CBD Virtue

“We are looking for larger premises due to growing demand and want to stay local. We employ 16 people and with the way things are going we are looking to double the workforce.”

Sales of products containing CBD have skyrocketed by 99 per cent in the UK, according to data.

Analysis by deals firm Wowcher suggests purchases of CBD products have almost doubled in 2019, with an increasing number of Brits trying the ingredient.

“The industry is exploding,” Mr Butler says. “Initially as a company we had a slow start with various issues with banks and online payment systems, but we have got more and more people on board who know how to get around these things.

Source: https://www.expressandstar.com/news/business/2019/10/17/it-is-quite-amazing-cbd-oil-entering-the-mainstream/

Tags: , , , , , , , , ,
Posted in All Recent Posts, North Bud Farms Inc | Comments Off on NORTHBUD $NBUD.ca – ‘It is quite amazing’: #CBD oil entering the mainstream $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Bougainville Ventures $BOG.ca – US retail sales of #CBD to increase 133% in 2019, surpass $10 billion by 2024 $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 5:41 PM on Thursday, October 17th, 2019

SPONSOR:  Bougainville Ventures Inc (CSE: BOG) provides strategic capital to the thriving cannabis cultivation sector through ownership and development of commercial real estate properties. The company also offers fully built out turnkey facilities equipped with state-of-the-art growing infrastructure to cannabis growers and processors. Click here for more info.

—————

US retail sales of CBD to increase 133% in 2019, surpass $10 billion by 2024

  • Retail sales of CBD in the U.S. are expected to surpass $1 billion in 2019 – a 133% increase over 2018 sales

DENVER, Oct. 17, 2019 — Retail sales of CBD in the U.S. are expected to surpass $1 billion in 2019 – a 133% increase over 2018 sales – and may eclipse $10 billion by 2024, according to projections from the newly released 2019 Hemp & CBD Industry Factbook, produced by the editors of Hemp Industry Daily.

The 2019 Hemp & CBD Industry Factbook predicts that retail sales of CBD in the U.S. are expected to surpass $1 billion in 2019 – a 133% increase over 2018 sales – and may eclipse $10 billion by 2024.

“The recent surge of consumer demand for CBD, coupled with increasingly easy access to CBD products, is expected to drive retail sales to about $1.1 billion-$1.3 billion in 2019,” said Kristen Nichols, editor of the 2nd Annual Hemp & CBD Industry Factbook. “We project retail CBD sales will increase to $10.3 billion by 2024, a five-year compound annual growth rate of 54%.”

When no federal agency tracks hemp as a commodity, the exclusively business focused 2019 Annual Hemp & CBD Industry Factbook provides understanding of the current and future challenges needed to make the most accurate and informed business decisions. Research-driven insights, will help business professionals understand economic, agricultural and regulatory developments impacting their positions and growth in the industry.

The 2019 Annual Hemp & CBD Industry Factbook offers:

  • 30+ charts exploring and analyzing the hemp & CBD market from critical angles including retail forecasts, consumer demand, production and more.
  • Top 10 hemp-producing state profiles exploring market conditions and retail trends.
  • Regulatory outlook, best practices, and future considerations for cultivators and processors looking to meet consumer demand
  • Benchmarks and wholesale prices, plus prices for hemp seeds and clone varietals
  • Pain points for growers and processors with a focus on input costs and per acre profits

“Imagine running a race with brand-new shoes and a burst of energy but no idea what the course looks like. That’s somewhat the position in which today’s hemp industry finds itself,” said Nichols. “Relying on deeply researched data points along the way could make the difference between hitting the finish line and running off course.”

Source: https://www.prnewswire.com/news-releases/us-retail-sales-of-cbd-to-increase-133-in-2019-surpass-10-billion-by-2024-300940056.html

Tags: , , , , , , ,
Posted in Bougainville Ventures | Comments Off on Bougainville Ventures $BOG.ca – US retail sales of #CBD to increase 133% in 2019, surpass $10 billion by 2024 $CROP.ca $VP.ca NF.ca $MCOA

North Bud Farms $NBUD.ca Announces the Appointment of Sean Homuth as Acting Chief Financial Officer $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 10:03 AM on Thursday, October 17th, 2019
  • Announce the appointment of Sean Homuth as Acting Chief Financial Officer, effective today
  • Mr. Homuth’s permanent role as CFO will commence upon receiving Health Canada security clearance required for all Officers and Directors of the Company

TORONTO, Oct. 17, 2019 — North Bud Farms Inc. (CSE: NBUD) (OTCQB: NOBDF) (“NORTHBUD” or the “Company”) is pleased to announce the appointment of Sean Homuth as Acting Chief Financial Officer (CFO), effective today. Mr. Homuth’s permanent role as CFO will commence upon receiving Health Canada security clearance required for all Officers and Directors of the Company. 

“As NORTHBUD expands its presence into the USA with the anticipated closing of its previously announced letters of intent with the Qlora Group (California) and Nevada Botanical Science (Nevada), we are strategically adding additional expertise in international business and finance,” said Ryan Brown, CEO of North Bud Farms Inc.

Mr. Homuth brings extensive experience with both Canadian and U.S. publicly traded organizations both in industry as well as from a client perspective during his tenure at Ernst & Young and, more recently, as an independent consultant. Previously, Mr. Homuth was Chief Financial Officer at Orezone Gold Corporation (and Vice President, Finance and Administration for its predecessor company, Orezone Resources Inc.) a publicly listed company headquartered in Canada with operations in West Africa. At Orezone Mr. Homuth led a global team of finance professionals and was involved in over $800 million in financings and M&A transactions with the company and its predecessor. Mr. Homuth holds accounting designations in both Canada (CPA, CA) and the United States (CPA – Illinois).

“We are pleased to welcome Sean to our dynamic team as NORTHBUD expands its footprint into the USA,” stated Ryan Brown, CEO of North Bud Farms Inc. “Sean brings specialty experience in accounting and finance for international companies as well as a profound knowledge of capital markets, having worked with and advised many public companies over the years. He joins NORTHBUD at an exciting time in its development as his leadership and experience will be essential in executing our strategic plan and taking the company to its next level of growth.”

Brendan Stutt, the Company’s incumbent CFO, who has made invaluable contributions to the Company’s financial leadership and culture, will work to ensure a smooth transition and will remain with the Company in a non-executive role.

Mr. Brown stated: “We would like to thank Brendan for his contributions to the Company, in particular the successful listing of NORTHBUD on the Canadian Securities Exchange.” 

About North Bud Farms Inc.
North Bud Farms Inc., through its wholly owned subsidiary GrowPros MMP Inc., is pursuing a licence under The Cannabis Act. The Company has built a state-of-the-art purpose-built cannabis production facility located on 135 acres of Agricultural Land in Low, Quebec, Canada. NORTHBUD through its wholly owned U.S. subsidiary, Bonfire Brands USA has entered into agreements to acquire assets in California and Nevada.

For more information visit: www.northbud.com

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Certain statements and information included in this press release that, to the extent they are not historical fact, constitute forward-looking information or statements (collectively, “forward-looking statements”) within the meaning of applicable securities legislation. Forward-looking statements, including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. This press release contains forward- looking statements including those relating to the entering into of the Definitive Agreement and closing of the Transaction with the Qlora Group and Nevada Botanical Science. Forward-looking statements are based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risk factors included in the Company’s final long form prospectus dated August 21, 2018, which is available under the Company’s SEDAR profile at www.sedar.com. Accordingly, readers should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statements to reflect information, events, results, circumstances or otherwise after the date hereof or to reflect the occurrence of unanticipated events, except as required by law including securities laws. This news release does not constitute an offer to sell or a solicitation of any offer to buy any securities of the Company.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
[email protected]

Tags: , , , , , , , , ,
Posted in North Bud Farms Inc | Comments Off on North Bud Farms $NBUD.ca Announces the Appointment of Sean Homuth as Acting Chief Financial Officer $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Bougainville Ventures $BOG.ca – CBD Demand Soars With a Growing Number of Uses $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 1:27 PM on Tuesday, October 15th, 2019

SPONSOR:  Bougainville Ventures Inc (CSE: BOG) provides strategic capital to the thriving cannabis cultivation sector through ownership and development of commercial real estate properties. The company also offers fully built out turnkey facilities equipped with state-of-the-art growing infrastructure to cannabis growers and processors. Click here for more info.

CBD Demand Soars With a Growing Number of Uses

  • Global cannabidiol market is expected to grow from USD 1.04 Billion in 2018 to USD 16.32 Billion by 2026 while registering a CAGR of 27.7% during the forecast period, according to data compiled by Reports and Data

NEW YORK, Oct. 15, 2019 – As the medical industry continues to evolve, researchers are actively looking for innovative remedies and treatments for patients. Notably, cannabis has become the topic of discussion after numerous researchers and institutions highlighted its therapeutic benefits. However, despite medical advancements throughout the cannabis industry, most federal regulators around the world have not yet moved to fully legalize cannabis for medical applications because of the psychotropic effects associated with it. Nevertheless, several regulators have decided to legalize cannabidiol, or CBD, a compound found within cannabis. CBD is a derivative found within the cannabis plant, however, unlike its tetrahydrocannabinol, or THC, counterpart, it does not induce psychoactive effects. Consequently, regulators became more inclined to legalize CBD. Primarily, the CBD industry is being accelerated by the healthcare segment.

Specifically, countries such as Australia, Canada, France, Germany, Italy, the U.K. and the U.S. have all adopted CBD-related legislation. Overall, the therapeutic grade segment dominates that overall CBD market because of increasing demand from innumerable applications. The segment accounted for 58.6% of the overall CBD market share and is expected to continue its dominance. In particular, the healthcare segment is expected to account for a total of USD 10.28 Billion of the CBD market by 2026. Moreover, the food and beverage industry is also expected to witness exponential growth. And while the U.S. and Canada are the primary drivers for the global CBD market, other international markets are also expected to greatly contribute. For instance, the Asia Pacific market is anticipated to reach USD 3.1 Billion by 2026 and exhibit a CAGR of 29.5%, while the European market is projected to grow at a CAGR of 28.9%. As a result, the global cannabidiol market is expected to grow from USD 1.04 Billion in 2018 to USD 16.32 Billion by 2026 while registering a CAGR of 27.7% during the forecast period, according to data compiled by Reports and Data.

The pharmaceutical segment of the CBD industry is expected to witness significant R&D investments to accelerate deployment and meet the medical needs of a number of diseases. Specifically, researchers have uncovered that CBD can treat a variety of diseases such as chronic pain, anxiety, depression, and cancer. And while most of these conditions would likely require a prescription from a medical practitioner, there are over-the-counter or OTC products that consumers can easily purchase at their local convenience stores in the U.S. or Canada. Consumers can purchase CBD-based products such as tinctures, topicals, patches, capsules, foods, and beverages. Typically, most OTC products are marketed as health and wellness products that are aimed to relieve minor ailments. For instance, many health and wellness retailers promote CBD as a way to stimulate relaxation or relieve small headaches. Notably, major pharmaceutical retailers such as CVS or Walgreens have also decided to add CBD products to their shelves. The two corporations added CBD products in order to provide consumers with cheaper and alternative care products. “It really does help normalize this. If Grandma can go to the store and get it, now the conversation about cannabis is going to be very different,” said Michele Ross, PhD, MBA, Research Director at Decriminalize California. “CBD business is already huge. But normalizing the culture around taking these products is going to open the door for more people to feel comfortable investing in these types of businesses. It opens up the possibility for them to be sold in more stores.”

Source: https://www.prnewswire.co.uk/news-releases/cbd-demand-soars-with-a-growing-number-of-uses-815946592.html

Tags: , , , , , , ,
Posted in Bougainville Ventures | Comments Off on Bougainville Ventures $BOG.ca – CBD Demand Soars With a Growing Number of Uses $CROP.ca $VP.ca NF.ca $MCOA

The Miracle That Is #CBD, Might Help Breast Cancer Patients Too – SPONSOR: Empower Clinics $CBDT $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 12:08 PM on Friday, October 11th, 2019

SPONSOR:

Why Empower Clinics

  • A leading owner/operator of physician staffed health and pain management clinics
  • Patient database of over 165,000 patients 
  • Platform generating $4MM USD in revenue annually (2019)
  • Proprietary technology platforms including Electronic Health Records portal and e-Commerce for CBD product distribution
  • Launching CBD extraction facility
  • First extraction system capacity = 6,000 Kg per year.
  • CBD based products are poised to be a $20B global industry by 2022
  • Medical cannabis is poised to be a $100B global industry by 2025

The Miracle That Is CBD, Might Help Breast Cancer Patients Too

By: Erika W. Smith  

CBD is in our lattes, moisturizers, and chocolates, but what about its use in a hospital setting instead of your local café or beauty store? Although more study is needed, research suggests that CBD may have the potential to help relieve certain side effects of chemotherapy.  

CBD is short for cannabidiol, which is one of the many compounds found in cannabis and hemp. Unlike tetrahydrocannabinol (THC), it’s non-psychoactive. Manufacturers have found a way to separate CBD from the plants, and the Agriculture Improvement Act of 2018 (aka the Farm Bill) legalized hemp-derived CBD that contains no more than 0.3% THC and is made from hemp grown by licensed producers. (That’s why you’ve seen so many CBD products recently.) But so far, the Food and Drug Administration has only approved one form of CBD: Epidiolex, a drug containing a purified marijuana-derived form of CBD, which is used for preventing seizures caused by rare forms of epilepsy. 

However, medical marijuana — which contains CBD as well as THC and other compounds — has been used by cancer patients for many years. In 1996, California became the first state to legalize marijuana for medical use. And although marijuana is still illegal on a federal level, it’s currently legal for medical use in 33 states — and it’s approved for use by cancer patients in every state in which medical marijuana is legal. (For comparison, medical marijuana is approved for use by patients with Crohn’s disease in only 27 states.) Additionally, the FDA has approved two chemically pure drugs based on marijuana compounds to treat nausea and vomiting in cancer chemotherapy patients.   

A 2016 review of medical marijuana’s use in oncology, published by the American Medical Association journal JAMA Oncology, notes, “Marijuana in oncology may have potential for use as an antiemetic [relieving nausea and vomiting], for refractory cancer pain, and as an antitumor agent. However, much of the data are based on animal data, small trials, or are outdated.” The authors concluded that more research is needed into medical marijuana’s therapeutic use for cancer patients.  

There is even less research into CBD’s potential benefits for cancer patients. But still, some studies have been conducted. According to the National Cancer Institute, research indicates that CBD may slow the growth or reduce the risk of recurrence of certain kinds of cancers, including breast cancer; enhance the potency of certain medications; and reduce chemotherapy side effects including vomiting, nausea, and anxiety. However, all these studies are limited, and experts agree that further research is needed to understand just how CBD affects humans.  

Source: https://www.refinery29.com/en-us/cbd-oil-breast-cancer

Tags: , , , , , , ,
Posted in Empower Clinics Inc. | Comments Off on The Miracle That Is #CBD, Might Help Breast Cancer Patients Too – SPONSOR: Empower Clinics $CBDT $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca

« Older Entries
Newer Entries »